ArticleMuscle & nerve2017
Erythropoietin accelerates functional recovery after moderate sciatic nerve crush injury.
Article in Muscle & nerve, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 32 citations in OpenAlex.
- The effects of topical erythropoietin on non-surgical treatment of periodontitis: a preliminary study.BMC oral health · 2021Trial
- Application ofActa histochemica et cytochemica · 2026Article
- Erythropoietin-PLGA-PEG as a local treatment to promote functional recovery and neurovascular regeneration after peripheral nerve injury.Journal of nanobiotechnology · 2022Article
- Delivery of nitric oxide-releasing silica nanoparticles forNeural regeneration research · 2022Article
- Erythropoietin promotes M2 macrophage phagocytosis of Schwann cells in peripheral nerve injury.Cell death & disease · 2022Article
- A Novel Standardized Peripheral Nerve Transection Method and a Novel Digital Pressure Sensor Device Construction for Peripheral Nerve Crush Injury.Bio-protocol · 2022Article
- Effect of Comprehensive Rehabilitation Training Program in Orthopedic Nursing of Patients with Residual Limb Injury Caused by Crush.Journal of healthcare engineering · 2022Article
- Novel Real-time Digital Pressure Sensor Reveals Wide Variations in Current Nerve Crush Injury Models.Military medicine · 2021Article
- An effective erythropoietin dose regimen protects against severe nerve injury-induced pathophysiological changes with improved neural gene expression and enhances functional recovery.International immunopharmacology · 2020Article
- Peripheral nerve injury and myelination: Potential therapeutic strategies.Journal of neuroscience research · 2020Review
- Article
- Pharmacological Attenuation of Electrical Effects in a Model of Compression Neuropathy.The Journal of bone and joint surgery. American volume · 2019Article
- 4-Aminopyridine as a Single Agent Diagnostic and Treatment for Severe Nerve Crush Injury.Military medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
introductionErythropoietin (EPO) has been identified as a neuroregenerative agent. We hypothesize that it may accelerate recovery after crush injury and may vary with crush severity.
methodsMice were randomized to mild, moderate, or severe crush of the sciatic nerve and were treated with EPO or vehicle control after injury. The sciatic function index (SFI) was monitored over the first week. Microstructural changes were analyzed by immunofluorescence for neurofilament (NF) and myelin (P
resultsIn moderate crush injuries, EPO significantly improved SFI at 7 days post-injury, an effect not observed with other severity levels. Increases in the ratio of P
conclusionsEPO accelerates recovery in moderately crushed nerves, which may be through effects on myelination and vascularization. Injury severity may influence the efficacy of EPO. Muscle Nerve 56: 143-151, 2017.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.